𝔖 Bobbio Scriptorium
✦   LIBER   ✦

G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain

✍ Scribed by F. Okada; T. J. Crow; G. W. Roberts


Publisher
Springer
Year
1990
Tongue
English
Weight
519 KB
Volume
79
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Subchronic haloperidol increases CB1 rec
✍ Mikael Andersson; Anton Terasmaa; Kjell Fuxe; Ingrid StrΓΆmberg πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 663 KB

The present study was designed to test whether chronic neuroleptic treatment, which is known to alter both expression and density of dopamine D 2 receptors in striatal regions, has effects upon function and binding level of the cannabinoid CB 1 receptor in the basal ganglia by using receptor autorad

Glutamate receptors in the postmortem st
✍ J. Thomas Noga; Thomas M. Hyde; Mary M. Herman; Christopher F. Spurney; Llewelly πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 332 KB πŸ‘ 1 views

## Introduction: Previous postmortem studies of glutamate receptors and uptake sites have shown decreased d-aspartate (d-asp) (a marker for the high affinity glutamate uptake site) and elevated (+)-5-methyl-10,11-dihydro-5h-dibenzo [a,d]cyclohepten-5,10-imine maleate (mk-801) binding in the putamen

The Role of the Thalamus and Basal Gangl
✍ S. Hua; S. G. Reich; A. T. Zirh; V. Perry; P. M. Dougherty; F. A. Lenz πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 246 KB

The mechanism of parkinsonian tremor may involve a central oscillator, peripheral feedback to the central nervous system (CNS), or both. The thalamus or the globus pallidus is the most likely site for a central oscillator and would be predicted to generate thalamic tremor-related activity characteri

Striatal and extrastriatal dopamine in t
✍ Yoland Smith; Rosa Villalba πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 261 KB

Degeneration of the nigrostriatal dopaminergic system is the characteristic neuropathological feature of Parkinson's disease and therapy is primarily based on a dopamine replacement strategy. Dopamine has long been recognized to be a key neuromodulator of basal ganglia function, essential for normal